Celltrion announced its acquisition of iQone Healthcare Switzerland, strengthening its presence in Europe, driving growth and expanding access to its biosimilar treatments.
iQone Healthcare Switzerland is an independent Swiss-based specialty pharmaceutical company dedicated to the commercialization of biosimilars and innovative treatments for rare diseases. Through its long-standing collaborations with several global pharmaceutical developers and manufacturers, iQone Healthcare provides a continually expanding selection of leading biosimilars and products to healthcare professionals and institutions in Switzerland.
Celltrion is a leading biopharmaceutical company, specializing in the research, development, and manufacture of small molecules, biosimilars, and innovative drugs. During fiscal year 2023, the company generated $1.66 billion of revenue, $694 million of EBITDA and net income of $409 million.
Upon completion, iQone Healthcare Switzerland will become a wholly-owned subsidiary of Celltrion Healthcare Hungary Kft. The deal will also provide Celltrion access to in-licensing opportunities, further strengthening its pipeline of therapies. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, the GI Alliance acquisition marks the 57th Pharmaceutical transaction of 2024. There were 107 Pharmaceutical deals announced during 2023, and 96 announced during 2022. Additionally, this marks the 11th deal announced in Switzerland during 2024. There were 14 Switzerland-based deals announced during 2023, and 10 announced during 2022.
